EUCTR2010-023241-29-GB进行中（未招募）不适用
A Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Obeticholic Acid (INT-747) for the Treatment of Portal Hypertension (PESTO) - Pilot Study Of Obeticholic Acid In Portal Hypertension
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients of age 18-70 years.
- •2. Patients must have a history of alcoholic cirrhosis with confirmed evidence of cirrhosis
- •3. Evidence of a feature of portal hypertension (endoscopic, radiological or other).
- •4. Patients recruited into the cohort for evaluation of effects on portal hypertension must have significant portal hypertension defined as a hepatic venous pressure gradient (HVPG) =12 mmHg.
- •5. Patients with large or grade 3 oesophageal varices as identified by endoscopy within six months of screening should be in an endoscopic band ligation program at the time of study entry.
- •6. Patients will be understood to be either abstaining from alcohol for at least 6 weeks, or have a stable low alcohol intake (= 4 units per day) for at least 6 weeks, and commit to stay abstinent or to consume = 4 units per day for the duration of the study.
- •7. Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least 1 effective (=1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least 1 effective method of contraception with all sexual partners unless they have had a prior vasectomy. Effective methods of contraception are considered to be:
- •Barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or
- •Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or
- •Intrauterine device (IUD); or
- •Vasectomy (partner)
- •8. Must be willing and able to give written informed consent and agree to comply with the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •Patients will be excluded from the study if they meet any of the following:
- •1. Patients with co-existing disease including:
- •Significant organ failure defined as:
- •o Respiratory: PaO2 <8kPa
- •o Renal: serum creatinine >150 µmol/L
- •o Cardiovascular: haemodynamic requirement for inotropic support
- •o CNS: hepatic encephalopathy West Haven Criteria score >2
- •Decompensated cirrhosis with a Child-Pugh score >12 or requirement for organ support
- •Concomitant hepatobiliary disease (except hepatitis B or C viral disease), e.g., primary sclerosing cholangitis, primary biliary cirrhosis
- •Known or suspected hepatic or extra hepatic malignancy, unless adequately treated or in complete remission for = 3 years
- •Concomitant acute pancreatitis
- •Acute alcoholic hepatitis with sepsis, within 3 months
- •2. Use of treatments for hepatitis B or C virus within 12 months of randomisation, or anticipated use during the study.
- •3. Use of the following drugs within 6 months of randomisation:
- •Immuno-modulatory treatment (including azothiaprine, methotrexate, anti-TNF therapies)
- •4. Use of concomitant vasoactive drugs within 4-6 weeks (as specified below) of randomisation:
- •Beta blockers (= 6 weeks prior to randomisation or, following one-off short term treatment of up to a maximum of 6 days = 3 weeks prior to randomisation)
- •Nitrates (= 6 weeks prior to randomisation)
- •Vasopressin or analogues (= 6 weeks prior to randomisation)
- •Phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil or other drugs for erectile dysfunction) = 4 weeks prior to randomisation)
- •5. Use of the following drugs within 3 months of randomisation:
- •Systemic corticosteroids
- •Pentoxifylline
- •Potentially hepatotoxic drugs (including a methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin), unless well tolerated, and approved by the medical monitor
- •Ursodeoxycholic acid (UDCA)
- •Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
- •6. Change in dose or regimen within 3 months of randomisation of:
- •Fibrates or statins
- •Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
- •7. Presence of human immunodeficiency virus (HIV)
- •8. If female: pregnant, lactating, or positive serum or urine pregnancy test
- •9. BMI =40, or =35 with complications
- •10. Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure)
- •11. Any patient who has received any investigational drug or device within 4 months of dosing, or who is scheduled to receive another investigational drug or device during the course of this study.
- •12. Known iodine allergy or sensitivity to contrast media
研究者
相似试验
进行中（未招募）
不适用
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-ATIntercept Pharmaceuticals Inc78
进行中（未招募）
1 期
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-BEIntercept Pharmaceuticals Inc78
进行中（未招募）
1 期
A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.Patients with acute mieloyd leukemia (AML)MedDRA version: 20.1Level: LLTClassification code 10024349Term: Leukemia myeloidSystem Organ Class: 100000004864EUCTR2018-000482-36-ESOryzon Genomics S. A.30
进行中（未招募）
1 期
Study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancerEUCTR2018-000469-35-ESOryzon Genomics S. A.33
已完成
不适用
A preliminary study to examine and evaluate the effect of obeticholic acid (INT-747) for the treatment of portal hypertension in patients with alcoholic liver diseaseCirrhosisISRCTN22662520Intercept Pharmaceuticals Inc34